We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Nektar Therapeutics | LSE:0UNL | London | Ordinary Share | NEKTAR THERAPEUTICS ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 47.18 | 1,796 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 90.12M | -276.06M | -1.4471 | -0.74 | 9B |
TIDM0UNL TIDMIKK FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: Norges Bank (b) Owner or controller of interests and short N/A positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose Nektar Therapeutics, Inc relevant securities this form relates: Use a separate form for each offeror/offeree (d) If an exempt fund manager connected with an N/A offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: 07/10/2022 For an opening position disclosure, state the Opening position disclosure latest practicable date prior to the disclosure (f) In addition to the company in 1(c) above, is the Yes discloser making disclosures in respect of any other PureTech Health plc party to the offer? If it is a cash offer or possible cash offer, state "N/A" 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security: USD 0.0001 common Interests Short positions Number % Number % (1) Relevant securities owned and 1,696,851 0.90% /or controlled: (1) Relevant securities owned and /or controlled: (2) Cash-settled derivatives: (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 1,696,851 TOTAL: 0.90% All interests and all short positions should be disclosed. -Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b) Rights to subscribe for new securities (including directors' and other employee options) Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. a. Purchases and sales Class of relevant Purchase/sale Number of Price per unit security securities (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per unit relevant description e.g. opening/closing a reference security e.g. CFD long/short position, securities increasing/reducing a long/short position (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of Product Writing, Number of Exercise Type Expiry Option relevant description purchasing, securities price per e.g. date money paid security e.g. call selling, to which unit American, / received option varying option European per unit etc. relates etc. (ii) Exercise Class of relevant Product Exercising/ Number of Exercise price security description exercised against securities per unit e.g. call option (d) Other dealings (including subscribing for new securities) Class of relevant Nature of dealing Details Price per unit (if security e.g. subscription, applicable) conversion 4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none" (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none" (c) Attachments Is a Supplemental Form 8 (Open Positions) attached? NO Date of disclosure: 11/10/2022 Contact name: Stanislav Boiadjiev Telephone number: +47 2407 3000 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk . The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk . END
(END) Dow Jones Newswires
October 11, 2022 04:39 ET (08:39 GMT)
1 Year Nektar Therapeutics Chart |
1 Month Nektar Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions